{"filings":[{"id":90546,"accession_number":"0001005286-26-000018","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical Q1 revenue $23.2M (-34% YoY), net loss $15.0M, reaffirms FY2026 guidance","event_type":"earnings","confidence":"high","bullets":["Revenue $23.2M, down 34% from $35.2M; gross margin 19% vs 28% prior year.","Net loss $15.0M ($0.43 loss per diluted share) vs $14.8M loss year ago.","Adjusted EBITDA $1.0M, down $4.7M from $5.7M; operating expenses cut 52%.","Signed three new commercial site transfer programs in Q1; reaffirms full-year 2026 guidance.","Liquidity $38.1M (cash $20.8M, revolver $17.3M); free cash flow $3.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":23193000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.72,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100150,"accession_number":"0001005286-26-000007","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical reports transition period revenue $75.5M (+20% y/y), Adj. EBITDA $13.1M","event_type":"earnings","confidence":"high","bullets":["Revenue for seven-month transition period $75.5M, +20% vs prior comparable period; Q4 revenue $35.7M, +10% y/y.","Net loss for transition period $18.0M, improved from $30.6M; Adjusted EBITDA $13.1M, up from $2.6M.","Gross margin 31% vs 26%; operating expenses decreased 31% to $24.4M.","Signed five new programs during transition, including two commercial site transfer programs in Q4.","Liquidity of $38.9M at quarter end; mid-term target: 12% revenue CAGR, EBITDA margins >25%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100149,"accession_number":"0001005286-26-000002","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Lifecore Biomedical fiscal year change to calendar; 2026 annual meeting June 4, proposals due March 16","event_type":"other_material","confidence":"high","bullets":["Board changed fiscal year from May-ending to calendar year, effective May 26, 2025 – Dec 31, 2025.","2026 Annual Meeting set for June 4, 2026, more than 30 days from prior Oct 29, 2025 meeting.","Deadline for shareholder proposals/nominations under Rule 14a-8 or otherwise is March 16, 2026.","Proposals must comply with SEC rules, Bylaws, and Delaware law; send to Chaska, MN address."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100148,"accession_number":"0001628280-26-002400","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lifecore Biomedical adopts Incentive Bonus Plan for executives and key employees","event_type":"other","confidence":"high","bullets":["Plan effective Jan 14, 2026; covers executive officers and selected employees.","Bonus payments based on achievement of financial/operational/strategic targets set by Compensation Committee.","Committee has discretion over participants, targets, weights, and adjustments for unusual events.","Includes clawback via existing Recoupment Policy adopted Nov 30, 2023.","No specific bonus targets or amounts disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116482,"accession_number":"0001005286-25-000150","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lifecore changes fiscal year to calendar year, effective May 26, 2025","event_type":"other_material","confidence":"high","bullets":["Board approved fiscal year change on Aug 1, 2025; new calendar year ends Dec 31.","Transition period of ~7 months from May 26, 2025 to Dec 31, 2025.","Prior fiscal year ended May 25, 2025 (FY2025); prior periods not adjusted.","Presentation used at Jefferies Healthcare Conference in November 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116481,"accession_number":"0001005286-25-000146","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical Q1 revenue up 26% to $31.1M; Adjusted EBITDA turns positive at $3.1M","event_type":"earnings","confidence":"high","bullets":["Revenue $31.1M (+26% YoY), driven by HA manufacturing (+$4.8M) and CDMO growth.","Net loss narrowed to $10.0M ($0.29 loss per share) from $16.2M ($0.53) a year ago.","Adjusted EBITDA of $3.1M vs negative $1.8M in prior year; SG&A down $5.9M.","Affirms transition period guidance: revenue $74-76M, Adjusted EBITDA $12-14M.","Signed 4 new programs (2 post-quarter); commercial site transfer with large pharma."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":31109000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116480,"accession_number":"0001005286-25-000138","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lifecore Biomedical stockholders elect nine directors and ratify KPMG at 2025 annual meeting","event_type":"other_material","confidence":"high","bullets":["Katrina L. Houde, Humberto C. Antunes, Paul H. Johnson, Paul Josephs, Matthew E. Korenberg, Nelson Obus, Joshua E. Schechter elected by common and Series A holders.","Series A preferred stockholders elected Jason Aryeh and Christopher S. Kiper as directors with 38,776 votes for each.","Ratification of KPMG LLP as independent auditor for fiscal 2025 received 35,663,643 votes for, 15,326 against.","Non-binding advisory vote on named executive officer compensation approved with 24,642,130 votes for, 238,354 against.","A total of 37,436,784 common shares and 46,593 Series A preferred shares were outstanding on the record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132939,"accession_number":"0001005286-25-000133","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lifecore Biomedical approves CY 2025 transition bonus plan; CEO target 100% of base salary","event_type":"other_material","confidence":"high","bullets":["New bonus plan covers the approximate seven-month transition period May 26, 2025 through Dec 31, 2025.","Bonus weighted 80% on Adjusted EBITDA and total revenue, 10% on individual objectives, 10% on company goals.","Target bonus as % of transition-period base salary: CEO Paul Josephs 100%, CFO Ryan Lake 60%, Chief Legal Tom Salus 50%.","Maximum payout capped at 200% of target level for financial goals; minimum Adjusted EBITDA threshold applies.","CY 2025 plan replaces the prior FY 2026 Bonus Plan terminated due to the fiscal year change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132938,"accession_number":"0001005286-25-000118","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Lifecore Biomedical dismisses BDO and appoints KPMG as new independent auditor","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved appointment of KPMG on August 12, 2025 as independent registered public accounting firm for transition period ending December 31, 2025.","BDO was dismissed on August 12, 2025; its audit reports for fiscal years ended May 26, 2024 and May 25, 2025 did not contain adverse opinions.","BDO's reports stated internal control material weaknesses existed as of May 26, 2024 and May 25, 2025 based on COSO criteria.","No disagreements or reportable events occurred between Lifecore and BDO during the covered periods.","Material weaknesses included deficiencies in control environment, risk assessment, and monitoring as previously disclosed in the Annual Report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132937,"accession_number":"0001005286-25-000115","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical files investor presentation under Regulation FD; no material updates visible in filing","event_type":"other","confidence":"low","bullets":["Filing furnishes a presentation dated August 12, 2025 for investor discussions.","No specific financial results, guidance, or material events disclosed in the filing body.","Full presentation content not included in provided text, limiting assessable news."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132936,"accession_number":"0001005286-25-000106","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifecore FY2025 revenue $128.9M meets guidance; net loss $38.7M; guides transition period $74-76M","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $36.4M (-4% YoY); net loss $1.1M vs $7.1M loss; adj. EBITDA $9.1M vs $10.4M.","FY2025 revenue $128.9M (+0.5% YoY); net loss $38.7M vs $12.0M income; adj. EBITDA $19.5M vs $20.2M.","Signed nine new customer programs in FY2025; post-quarter added GLP-1 obesity therapy and Phase 2 dermatology programs.","Transition period (May-Dec 2025) guidance: revenue $74-76M; adj. EBITDA $12-14M; net loss $19.8-17.8M.","Moving fiscal year to calendar year-end Dec 31, 2025; new ERP system planned for Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":8665000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132935,"accession_number":"0001005286-25-000097","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lifecore Biomedical approves FY2026 bonus plan for executives with EBITDA, revenue targets","event_type":"other","confidence":"high","bullets":["Board approved FY2026 cash bonus plan for CEO Paul Josephs (100% target), CFO Ryan Lake (60%), and CAO Thomas Salus (50%).","Bonus weighted 80% to Adjusted EBITDA and development revenue; max payout 200% of target; no bonus if minimum EBITDA unmet.","Individual performance goals and company business goals each weighted 10%.","Salus receives 125% of any bonus earned per employment agreement; all bonuses subject to clawback policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149481,"accession_number":"0001005286-25-000072","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lifecore Biomedical increases Equity Inducement Plan by 750,000 shares to 4,250,000 total","event_type":"other_material","confidence":"high","bullets":["Board of Directors amended the Equity Inducement Plan on April 11, 2025, adding 750,000 shares.","Total shares reserved for awards under the Plan increased to 4,250,000.","Shares may be issued as incentive stock options from authorized but unissued or treasury shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149480,"accession_number":"0001005286-25-000061","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lifecore Biomedical shareholders approve issuance of shares beyond 19.99% threshold","event_type":"other_material","confidence":"high","bullets":["At April 10, 2025 special meeting, stockholders approved the Issuance Proposal, allowing issuance of common stock underlying Series A Preferred Stock in excess of 19.99% of outstanding common shares.","Votes on Issuance Proposal: 24,098,218 For, 444,639 Against, 33,281 Abstain.","Adjournment Proposal was also approved (28,882,501 For) but not needed since Issuance Proposal passed.","The approval relates to the Securities Purchase Agreement dated January 9, 2023, with named investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149479,"accession_number":"0001005286-25-000052","cik":1005286,"company_name":"LIFECORE BIOMEDICAL, INC. DE","ticker":"LFCR","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lifecore Biomedical reports Q3 FY2025 revenue $35.2M, net loss $14.8M, sells unused filler for $17M","event_type":"earnings","confidence":"high","bullets":["Revenue $35.2M, down 2% YoY; CDMO revenue declined $1.5M, partially offset by HA manufacturing growth of $1.0M.","Net loss of $14.8M ($0.47 diluted loss per share) vs prior-year net income of $15.6M including $21M non-cash debt derivative gain.","Adjusted EBITDA $5.7M, down from $6.4M YoY; gross profit fell to $9.8M from $11.9M.","Sold unused high-speed isolator filler for $17M; $7M received at closing, remainder over 18 months. Signed multiple new development agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":92423000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}